TP53 and adenocarcinoma: The finding of the TP53/E2F7- and RB1/E2F1-mediated resistance mechanisms is clinically relevant since TP53 and RB1 are concurrently altered in 39% of mCRPC tumors with adenocarcinoma histology and 74% of mCRPC tumors with neuroendocrine features82,83.